Four years ago, Exact Sciences was roadkill. The company, based in greater Boston at the time, had been experimenting with molecular diagnostic technologies for more than a dozen years. It had a stellar scientific pedigree from founder Stanley Lapidus. But it had burned through more than $170 million of investor cash, and still had no convincing clinical trial data to support a market-ready diagnostic test.
Hey, check out all the engineering jobs. Post your resume today!
